Primary Immunodeficiency Clinical Trial
Official title:
A Multicenter, Randomized, Cross-over, Open-label Study to Evaluate IGSC 20% Flexible Dosing Including Daily Push Dosing In Treatment-Experienced Subjects With Primary Immunodeficiency (PI) and Evaluation of Loading/Maintenance IGSC 20% in Treatment-Naïve Subjects With PI
This is a prospective, multi-center, randomized, open-label, 2-period cross-over study (16
weeks per treatment period) to evaluate flexible dosing and daily push dosing of IGSC 20% in
treatment-experienced subjects with PI. An additional, separate cohort of treatment-naïve,
non-randomized subjects who will not be part of the crossover are included and will receive a
loading dose of 5 consecutive daily doses of IGSC 20% followed by weekly infusions of IGSC
20% starting Week 1 (Day 8) through Week 32 (end of Treatment Phase).
For treatment-experienced subjects, the study consists of a Screening Visit, Baseline Visit,
16-week Treatment Period 1, 16-week Treatment Period 2, and Final Visit/Early Termination
Visit. For treatment-naïve subjects, the study consists of a Screening Visit, a Baseline
Visit, a 32-week Treatment Phase, and Final Visit/Early Termination Visit.
Approximately 54 treatment-experienced subjects and approximately 6 treatment-naïve subjects
will be enrolled at study centers in the United States (US) and European Union (EU).
This is a prospective, multi-center, randomized, open-label, 2-period cross-over study (16
weeks per treatment period) to evaluate flexible dosing and daily push dosing of IGSC 20% in
treatment-experienced subjects with PI. There is an additional, separate cohort of
treatment-naïve, non-randomized subjects with PI who will not be part of the crossover.
Treatment-experienced subjects entering the study will maintain the same IgG dose (mg/kg)
received prestudy that will be normalized to the study-assigned dose-time interval (ie, there
will be 1:1 correspondence regardless of prestudy route of administration [intravenous [IV]
or SC]). Treatment-experienced subjects will be randomized in a 1:1:1 ratio into 1 of 3
parallel cohorts consisting of 18 subjects each as follows:
Cohort 1 (daily push compared with every 2 weeks [biweekly] pump) will evaluate syringe daily
push dosing versus every 2 weeks [biweekly] ambulatory pump administration. Subjects will be
randomized in a 1:1 ratio to 1 of 2 sequences, either beginning with syringe daily push
dosing for 16 weeks and then crossing over to ambulatory pump administration every 2 weeks
for 16 weeks or the reverse sequence.
Cohort 2 (daily push compared with once weekly pump) will evaluate syringe daily push dosing
versus once weekly ambulatory pump administration. Subjects will be randomized in a 1:1 ratio
to 1 of 2 sequences, either beginning with syringe daily push dosing for 16 weeks and then
crossing over to ambulatory pump administration once every week for 16 weeks or the reverse
sequence.
Cohort 3 (daily push compared with 2 times/week pump) will evaluate syringe daily push dosing
versus 2 times/week ambulatory pump administration. Ambulatory pump dosing will take place on
preselected days (eg, Monday and Thursday) not less than 3 days apart. The dosing days should
remain constant for the duration of the study. Subjects will be randomized in a 1:1 ratio to
1 of 2 sequences, either beginning with syringe daily push dosing for 16 weeks and then
crossing over to ambulatory pump administration 2 times/week for 16 weeks or the reverse
sequence.
The treatment-naïve cohort will receive a loading dose of 5 consecutive daily doses of IGSC
20% 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of 150 mg/kg starting Week
1 (Day 8) through Week 32 (end of Treatment Phase).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04561115 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
|
Phase 3 | |
| Recruiting |
NCT06355323 -
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
|
N/A | |
| Completed |
NCT04566692 -
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
|
Phase 4 | |
| Completed |
NCT01465958 -
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
|
Phase 4 | |
| Completed |
NCT01581593 -
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
|
Phase 3 | |
| Completed |
NCT02881437 -
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
|
Phase 4 | |
| Recruiting |
NCT06092528 -
Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency
|
N/A | |
| Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
| Completed |
NCT03907241 -
CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
|
Phase 3 | |
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Completed |
NCT02806986 -
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
|
Phase 3 | |
| Completed |
NCT03339778 -
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
|
N/A | |
| Enrolling by invitation |
NCT00895271 -
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
|
||
| Recruiting |
NCT03206099 -
NIAID Centralized Sequencing Protocol
|
||
| Completed |
NCT02503293 -
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
|
Phase 4 | |
| Recruiting |
NCT03610802 -
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
|
||
| Completed |
NCT03815357 -
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
|
||
| Completed |
NCT02269163 -
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
|
Phase 3 | |
| Terminated |
NCT03733249 -
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02123615 -
ASIS for GAMMAGARD in Primary Immunodeficiency
|
Phase 1/Phase 2 |